These results demonstrate that ABL kinase activity is required for
osteolytic metastasis in breast cancer and suggest that pharmacological inhibition of the ABL kinases may be an effective treatment for bone metastasis.
Our data raise the possibility that inhibition of ABL kinases can increase apoptosis of breast cancer cells and block osteoclast activation, which is required for
osteolytic metastasis.
Not exact matches
ADAMTS1 and MMP1 proteolytically engage EGF - like ligands in an
osteolytic signaling cascade for bone
metastasis
Decreased
metastasis by ABL - deficient breast cancer cells was accompanied by a significant reduction in the extent of hindlimb
osteolytic lesions, as determined by x-ray and micro — computed tomography (μCT) imaging (Fig. 2, I and J).